Attorney Docket No. Le A-36 411

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Achim Feurer, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/011452

Title: Heteroaryloxy-Substituted Phenylaminopyrimidines as Rho-Kinase Inhibitors

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

## **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Dr. Tilman Breitenstein

Limited Recognition Under 37 C.F.R. § 11.9(b)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2226 Facsimile: (203) 812-6459

	Form PTO-1449 (Modified)			U.S. Dep Patent	epartment and Tra				Serial No.	Art Unit	Filing	Filing Date / Atty, Docker No.		
INI	FORMA	ATION	n dis	CLOS	URE (	CITA'	TION		Applicant(s)		<u>,                                    </u>		Ise Arou	¥1 1~
	<u>,</u>									Achim FEURI	ER, et al.		******	
<u> </u>		<del></del>		- 20				S. PA	ATENT DOCU					
*	* DOCUM					IT NO.			DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	11	G DATE IF PRIATE
					1			<u> </u>						
			-	_		-	<u> </u>					<u> </u>		
		-	_		-	-	┼	-	-			<del> </del>		
<u> </u>		_	+-	-	-	_	-	-			-		-	
<u> </u>		-			+			-						
	+	-	-		—		-	+						<del></del>
		Ш.,	Ш_	Ш_	Ш_	<u> </u>			= : = : = : = : = : = : = : = : = : = :					
	т	<del></del>	···	- DOC				elgn ——	PATENT DO		POBLADV	CUD	T om ANIC	· · ·
*				DUC	CUMEN	TNU.			DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	YES	LATION NO
	F1	0	1	6	4	6	5	4	07/09/01	wo	1			
	F2	0	1	6	0	8	1	6	23/08/01	wo			,	
			<u></u>											
			<u> </u>		<u> </u>		<u> </u>	<u> </u>					<u> </u>	
	_		-	<del> </del>	<del> </del>	ļ	<u> </u>	<u> </u>		<u> </u>			•	<u> </u>
	<u> </u>		<u> </u>	<u> </u>						<u> </u>				
	R1								ding Author, Tinase Pathway				-1 Cytos	-1-olata]
	V.								nase Pathway ', TRENDS Pha					Keletai
				-					<del> </del>					
	+													
		<u> </u>												
<del> </del>	-	<del> </del>												
<b></b>														
													<del></del>	
	'													
EXAMIN	ER		_			_			DATE	CONSIDERED				
									is in conformance ation to applicant.	with MPEP 609. I	Draw line through	h citation if n	ot in confor	mance